发布求助
文献互助 智能选刊 最新文献

memo - Magazine of European Medical Oncology最新文献

筛选
英文 中文
Renal cell carcinoma 肾细胞癌
memo - Magazine of European Medical Oncology Pub Date : 2023-11-07 DOI: 10.1007/s12254-023-00918-w
Jasmin Spiegelberg
{"title":"Renal cell carcinoma","authors":"Jasmin Spiegelberg","doi":"10.1007/s12254-023-00918-w","DOIUrl":"https://doi.org/10.1007/s12254-023-00918-w","url":null,"abstract":"Summary Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women. Renal cell carcinoma (RCC) accounts for approximately 80% of all kidney cancer. This year’s American Society of Clinical Oncology (ASCO) Annual Meeting was held from 2–6 June 2023, in Chicago, USA. Combination therapies for advanced RCC continue to be of interest at ASCO 2023, with the presentation of updated results from some ongoing studies. There were several studies presented at ASCO looking at treatments for non clear renal cell carcinoma. Immunotherapy- based therapy regimes are now the gold standard for rare histological subtypes of RCC.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"30 6","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135475911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic testing and management of prostate cancer patients with pathogenic germline variants 前列腺癌致病种系变异患者的基因检测和管理
memo - Magazine of European Medical Oncology Pub Date : 2023-11-03 DOI: 10.1007/s12254-023-00921-1
Katharina Reiter, Melanie R. Hassler
{"title":"Genetic testing and management of prostate cancer patients with pathogenic germline variants","authors":"Katharina Reiter, Melanie R. Hassler","doi":"10.1007/s12254-023-00921-1","DOIUrl":"https://doi.org/10.1007/s12254-023-00921-1","url":null,"abstract":"Summary Prostate cancer (PCa) is an androgen-receptor signaling-dependent disease with a subset of patients harboring pathogenic germline variants (PGVs) in genes essential for DNA repair. In the last decade, several guidelines and recommendations have been developed to define which PCa patients should receive genetic testing to identify individuals at higher risk due to inherited alterations and to facilitate personalized treatment strategies. Notably, the presence of specific germline alterations in carriers undergoing PCa screening has implications for screening strategies, and PGV carriers with advanced disease are eligible to receive targeted therapies such as poly-ADP-ribose polymerase inhibitors (PARPi) or immune checkpoint inhibitors (CKI) depending on the alterations encountered. Although less information is available on carriers with localized disease, several trials are addressing this specific patient population and will help to collect data and improve clinical management of PCa patients with PGVs.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"50 10","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135819447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of malignant hypercalcemia in cancer patients—a short review 癌症患者恶性高钙血症的处理——一个简短的综述
memo - Magazine of European Medical Oncology Pub Date : 2023-11-03 DOI: 10.1007/s12254-023-00919-9
Clemens Petrasch, Petra Marics, Thomas Spanberger
{"title":"Management of malignant hypercalcemia in cancer patients—a short review","authors":"Clemens Petrasch, Petra Marics, Thomas Spanberger","doi":"10.1007/s12254-023-00919-9","DOIUrl":"https://doi.org/10.1007/s12254-023-00919-9","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"11 3‐4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135820266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction 5线her2定向治疗胃食管交界处转移性腺癌
memo - Magazine of European Medical Oncology Pub Date : 2023-10-27 DOI: 10.1007/s12254-023-00928-8
Sophie Roider-Schur, Sybille Machat, Leopold Öhler
{"title":"Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction","authors":"Sophie Roider-Schur, Sybille Machat, Leopold Öhler","doi":"10.1007/s12254-023-00928-8","DOIUrl":"https://doi.org/10.1007/s12254-023-00928-8","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"11 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136316455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma ASCO更新-肝细胞癌和胆管细胞癌
memo - Magazine of European Medical Oncology Pub Date : 2023-10-27 DOI: 10.1007/s12254-023-00929-7
Angela Djanani
{"title":"ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma","authors":"Angela Djanani","doi":"10.1007/s12254-023-00929-7","DOIUrl":"https://doi.org/10.1007/s12254-023-00929-7","url":null,"abstract":"Summary Two exciting phase 2 dates were presented at Asco. This results in a new phase III study for Hepatocelluar cancer that will be launched soon. With Cholangiocarcinoma there is a new substance that shows very good oberall response rates in a subgroup of patients.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136311461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment 针对PSMA受体的成像和治疗用于增强视力和精确治疗
memo - Magazine of European Medical Oncology Pub Date : 2023-10-19 DOI: 10.1007/s12254-023-00927-9
Sazan Rasul, Stephan Korn
{"title":"Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment","authors":"Sazan Rasul, Stephan Korn","doi":"10.1007/s12254-023-00927-9","DOIUrl":"https://doi.org/10.1007/s12254-023-00927-9","url":null,"abstract":"Summary In Europe, it is estimated that more than 65,000 men die each year from the consequences of advanced and metastatic prostate cancer (PCa). Currently, approximately 3.2 million European men are living with PCa. While the majority of PCa patients have favorable outcomes, the 5‑year relative survival rate for those with metastatic PCa is only 32%. Recent advances in the diagnosis of PCa have been boosted by the introduction of the prostate-specific membrane antigen (PSMA), which might identify patients with the most aggressive form of the disease. Molecular imaging with positron emission tomography (PET) targeting PSMA receptors (PSMA-PET) has utterly revolutionized the diagnosis and staging of PCa; however, its application is still under debate. On the one hand, there has been little progress in recent years in surpassing the limitations of androgen deprivation therapy (ADT), the backbone of metastatic PCa treatment. Adding additional systemic therapy became standard in the last few decades. Current ADT is only transiently effective, and patients eventually progress during ADT treatment, a condition known as castration-resistant PCa (CRPC). On the other hand, radioligand therapy (RLT) targeting these PSMA receptors, most commonly used in the studies [ 177 Lu]lutetium-PSMA-617, has been available for this cancer stage for nearly a decade and has been recently incorporated into the European Association of Urology (EAU) guidelines as a robust treatment option for patients with metastatic CRPC.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135778691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma her2阳性晚期胃食管腺癌的二线治疗
memo - Magazine of European Medical Oncology Pub Date : 2023-10-19 DOI: 10.1007/s12254-023-00924-y
Aysegül Ilhan-Mutlu, Ewald Wöll
{"title":"Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma","authors":"Aysegül Ilhan-Mutlu, Ewald Wöll","doi":"10.1007/s12254-023-00924-y","DOIUrl":"https://doi.org/10.1007/s12254-023-00924-y","url":null,"abstract":"Summary There is an unmet need for the treatment of patients with HER2-positive gastroesophageal tumors whose disease progressed on a first-line trastuzumab-based regimen. Several prospective trials took a targeted approach and evaluated various HER2-targeted agents as second-line therapy. However, these trials failed to demonstrate a survival benefit and were negative in primary endpoints. Recently, the antibody–drug conjugate trastuzumab deruxtecan has shown promise as a second-line treatment in patients with HER2-positive metastatic gastroesophageal tumors, with a remarkable overall response rate and a relevant prolongation of prognostic outcome. Several clinical trials will introduce more targeted therapy approaches with novel structures, which will hopefully further extend patients’ survival. This mini-review briefly summarizes the past practice of second-line treatment of HER2-positive gastroesophageal tumor patients, describes current knowledge based on recently published studies, and provides a short overview on the novel anti-HER2 compounds that are currently being clinically investigated and could yield positive results in the near future.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135730219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prognostic factors of long-term survivors with unresectable pancreatic cancer: a retrospective analysis 不可切除胰腺癌长期幸存者的预后因素:回顾性分析
memo - Magazine of European Medical Oncology Pub Date : 2023-10-17 DOI: 10.1007/s12254-023-00917-x
Giuseppe A. Colloca, Antonella Venturino
{"title":"Prognostic factors of long-term survivors with unresectable pancreatic cancer: a retrospective analysis","authors":"Giuseppe A. Colloca, Antonella Venturino","doi":"10.1007/s12254-023-00917-x","DOIUrl":"https://doi.org/10.1007/s12254-023-00917-x","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136032972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a real-life cohort of patients with cancer 在现实生活中的癌症患者队列中，对第四次SARS-CoV-2疫苗的细胞和体液反应
memo - Magazine of European Medical Oncology Pub Date : 2023-10-13 DOI: 10.1007/s12254-023-00916-y
Julia M. Berger, Pia Gattinger, Maximilian J. Mair, Anna S. Berghoff, Rudolf Valenta, Matthias Preusser
{"title":"Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a real-life cohort of patients with cancer","authors":"Julia M. Berger, Pia Gattinger, Maximilian J. Mair, Anna S. Berghoff, Rudolf Valenta, Matthias Preusser","doi":"10.1007/s12254-023-00916-y","DOIUrl":"https://doi.org/10.1007/s12254-023-00916-y","url":null,"abstract":"Summary This study assessed cellular and humoral responses to the fourth dose of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with malignant diseases. Even though, clear indications of humoral, cellular, or combined response was evident in most patients undergoing active treatment, high intra- and interpatient heterogeneity in response patterns was observed.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135856254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term survival and follow-up care after cancer in Austria 奥地利癌症后的长期生存和随访护理
memo - Magazine of European Medical Oncology Pub Date : 2023-09-01 DOI: 10.1007/s12254-023-00895-0
Alexandra Böhm
{"title":"Long-term survival and follow-up care after cancer in Austria","authors":"Alexandra Böhm","doi":"10.1007/s12254-023-00895-0","DOIUrl":"https://doi.org/10.1007/s12254-023-00895-0","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"90 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135305087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信